ALT Q2 2021 Earnings — Altimmune, Inc. Revenue & Financial Results | Market Cap Arena

ALTAltimmune, Inc.

$331M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$137,000-81.0% YoY

Gross Profit

-$13M-9587.6% margin

Operating Income

-$25M-18148.9% margin

Net Income

-$25M-18121.9% margin

EPS (Diluted)

$-0.60

QoQ Revenue Growth

-83.7%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$27M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$257M

Total Liabilities

$16M

Stockholders' Equity

$241M

Cash & Equivalents

$174M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$137,000	$721,636	-81.0%
Gross Profit	-$13M	$721,636	-1920.2%
Operating Income	-$25M	-$18M	-35.0%
Net Income	-$25M	-$17M	-48.1%

Revenue Segments

Grant

$100,000100%